Our extensive analysis divulged that a high expression score of S100A8 was associated with worse survival (PFI, OS, and DSS; p < 0.05) of breast cancer patients in METABRIC cohorts (Figure 5D and the OS data were validated in the SCAN-B cohort of 3273 patients (HR = 1.799, CI 95%; 1.451–2.231, log-rank p = 0.0000001) (Figure not included)). This evidence concerns the gene S100A8 and breast carcinoma.